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Mammalian APE1 controls miRNA processing and
its interactome is linked to cancer RNA metabolism
Giulia Antoniali 1, Fabrizio Serra1,8, Lisa Lirussi1,9, Mikiei Tanaka2, Chiara D’Ambrosio3,
Shiheng Zhang4, Slobodanka Radovic5, Emiliano Dalla6, Yari Ciani6, Andrea Scaloni3, Mengxia Li4,
Silvano Piazza 6,7 & Gianluca Tell 1
Mammalian apurinic/apyrimidinic endonuclease 1 is a DNA repair enzyme involved in
genome stability and expression of genes involved in oxidative stress responses, tumor
progression and chemoresistance. However, the molecular mechanisms underlying the role
of apurinic/apyrimidinic endonuclease 1 in these processes are still unclear. Recent ﬁndings
point to a novel role of apurinic/apyrimidinic endonuclease 1 in RNA metabolism. Through
the characterization of the interactomes of apurinic/apyrimidinic endonuclease 1 with RNA
and other proteins, we demonstrate here a role for apurinic/apyrimidinic endonuclease 1 in
pri-miRNA processing and stability via association with the DROSHA-processing complex
during genotoxic stress. We also show that endonuclease activity of apurinic/apyrimidinic
endonuclease 1 is required for the processing of miR-221/222 in regulating expression of the
tumor suppressor PTEN. Analysis of a cohort of different cancers supports the relevance of
our ﬁndings for tumor biology. We also show that apurinic/apyrimidinic endonuclease 1
participates in RNA-interactomes and protein-interactomes involved in cancer development,
thus indicating an unsuspected post-transcriptional effect on cancer genes.
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The human apurinic/apyrimidinic endonuclease 1 (APE1) isa multifunctional DNA repair protein belonging to thebase excision repair (BER) pathway. APE1 also plays non-
repair roles in the regulation of the expression of human genes
during oxidative stress1. Besides ﬁlling a crucial role in the
maintenance of genome stability, APE1 also acts as a master
regulator of the cellular response to genotoxic damage via direct
and indirect mechanisms. We recently characterized a direct role
of APE1 in the transcription of the SIRT1 gene through the
binding of nCaRE-sequences present on its promoter, demon-
strating that BER-mediated DNA repair may promote the
initiation of transcription of the SIRT1 gene in response to oxi-
dative DNA damage2. APE1 may also inﬂuence the onset of
inﬂammatory and metastatic progression through its redox-
mediated stimulation of DNA-binding activity of numerous
transcription factors3 regulating cancer-related genes.
Importantly, by regulating expression of the multidrug resistance
gene MDR14, 5 and the phosphatase and tensin homolog (PTEN)
tumor suppressor6, 7, APE1 has been implicated in chemoresis-
tance. Only recently has it been hypothesized that this
protein may play an unsuspected function in RNA metabolism
affecting gene expression8–10. Therefore, studying overlooked
roles of APE1 addresses several unsolved questions in
cancer biology. Accordingly, we and others have started
to unravel the molecular involvement of APE1 in RNA
processing11–13.
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Fig. 1 miRNA proﬁling of H2O2-treated and APE1-knocked down HeLa cells. a Hierarchical-clustering analysis showing miRNAs differentially expressed in
HeLa cell clones stably transfected with scrambled siRNA control (SCR), with an APE1 siRNA (siAPE) or SCR after stimulation with 1 mM H2O2 for 15min.
The heatmap diagram shows the centered miRNA expression values in logarithmic scale across the three groups of samples. b Empirical cumulative
distribution function (ECDF) curves for expression changes (log fold change) of miRNAs-target genes (red line) vs. those of random mRNAs (blue line).
Statistical signiﬁcance of the difference between ECDFs is indicated (P-value from Kolmogorov–Smirnov (KS) test and Wilcoxon (WC))
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The above-mentioned functions of APE1 are modulated
through interactions with several protein partners, some involved
in ribosome biogenesis and RNA processing (e.g., nucleophosmin
1 (NPM1) and nucleolin (NCL))14. Disruption of this interaction
network might impair BER function9, 15, as we recently demon-
strated in acute myeloid leukemia (AML) cells expressing a
mutated form of the nucleolar protein NPM116. In that and
additional works, we and others showed that APE1: (i) binds,
in vitro, structured RNA molecules via its 33 amino acids N-
terminal domain17; (ii) cleaves abasic single-stranded RNA, tak-
ing part in RNA-decay dependent on its endonuclease activity;
(iii) has 3ʹ-RNA phosphatase and 3ʹ-exoribonuclease activities;
(iv) regulates c-Myc mRNA levels and half-life in tumor cells18.
Interestingly, no other known enzyme seems to be devoted to the
removal of abasic or oxidized RNA or the removal of 3ʹ-phos-
phates of RNA molecules.
Damage to RNA such as oxidation or abasic site formation,
may have profound effects on gene expression and is emerging as
a common feature in different human pathologies, including
cancer19. Oxidized RNA20 or RNA-containing abasic sites21 show
inhibitory effects on reverse transcriptase activity, and oxidized
mRNA22 or mRNA with abasic sites23 exhibit compromised
translation activity and ﬁdelity24. Oxidation of miRNAs may also
regulate cellular events by modulating their effects on the speciﬁc
target gene25. Therefore, control of the processing and decay of
miRNAs during genotoxic stress may represent an important
mechanism of chemoresistance in cancer cells.
By using APE1 knockdown models, we and others have
demonstrated the pleiotropic ability of this protein to regulate the
expression of hundreds of genes associated with cancer cell
proliferation, invasion and chemoresistance14, 26. Possible
changes in miRNA processing underlying these effects have not
generally been investigated. Interestingly, in AML cells expressing
cytoplasmic NPM1 (NPM1c+) that alters APE1 endonuclease
function and intracellular location16, there is dysregulation of
miR-221/222 processing27. Strikingly, since it was previously
demonstrated that miR-221/222 regulate the expression of the
oncosuppressor PTEN28–30, a plausible hypothesis could be that
APE1 functional dysregulation may impact on gene expression
through miRNome regulation. An exhaustive list of target genes
(i.e., RNAs and mRNAs), miRNAs and ncRNAs directly
regulated by APE1 during cell response to genotoxic treatment
and that may speciﬁcally mediate cancer cell resistance to
chemotherapy is still lacking to date.
The present work aims at testing whether APE1 may indirectly
regulate gene expression through post-transcriptional mechan-
isms involving miRNAs processing and/or RNA regulation.
Altogether, our data provide major insights into APE1-regulated
transcriptome and APE1-regulated interactome, and suggest that
APE1–miRNA processing, under genotoxic stress conditions,
may represent a new paradigm of miRNA regulation in cancer
biology with relevance on chemoresistance.
Results
miRNA proﬁling of H2O2-treated and APE1-depleted HeLa
cells. We hypothesized that APE1 modulates a cellular response
to oxidative stress through post-transcriptional regulation of
miRNA expression. This hypothesis was tested in two ways. We
ﬁrst tried to identify whether miRNAs regulated by early times
of H2O2-treatment are involved in the regulation of PTEN,
a known APE1 target gene6, 7, 29, 30. We also evaluated whether
APE1-knockdown (APE1-kd) was associated with a signiﬁcant
alteration in the overall miRNome proﬁle. We did not combine
both conditions (i.e., oxidative stress and APE1-kd) in order to
avoid selection of off-targets effects due to non-speciﬁc triggering
of DNA damage response (DDR) by simultaneously exposing the
cells to oxidative damage in a context of BER-deﬁciency. For the
ﬁrst test, we performed a high-throughput miRNA expression
analysis of HeLa cells upon acute oxidative stress. For the
second, we studied the effect of APE1-silencing on the overall
miRNome proﬁle. We used HeLa cell clones stably transfected
with: (i) scrambled siRNA control (SCR), treated or not with
1 mM H2O2 for 15 min; and (ii) inducible APE1-speciﬁc siRNA
(siAPE1 or APE1-kd) cells14 (Fig. 1a, Supplementary Table 1 and
Supplementary Fig. 1a).
The NanoString nCounter Human v2 miRNA Expression
platform was used to obtain miRNome proﬁles. By using a
hierarchical-clustering approach and principal components
analysis, we were able to conﬁrm the good reproducibility
of the data obtained in the biological replicates (Supplementary
Fig. 1b, c).
The comparison between the SCR upon H2O2-treatment
and the SCR alone showed 26 upregulated (e.g., miR-221-3p,
miR-134, and miR-9-5p) and four downregulated miRNAs
(i.e., miR-494, miR-548aa, and miR-548ai) out of 800 total
proﬁled molecules (≥1 logFC, q-value ≤0.1) (Fig. 1 and
Supplementary Data File 1). A consistent number of miRNAs
was induced by the H2O2-treatment, in accord with previous
studies25. Interestingly, miR-221, which targets the PTEN
gene,29, 31 represented an ideal candidate to further test our
general hypothesis (see below). In the second set of experiments,
APE1-kd downregulated 55 miRNAs (including miR-484, miR-
635, and miR-410), with none upregulated, compared to the SCR
control (Supplementary Data File 1). The latter result was in line
with previous work, in which human osteosarcoma cells (HOS)
were transfected with APE1 siRNA26. In fact, 4 out of 12 miRNAs
that were downregulated in HOS (i.e., let-7i-5p, miR-324-5p,
miR-421, and miR-484) were also signiﬁcantly downregulated in
APE1-kd HeLa cells. Four other transcripts showed logFC
expression values below the applied cutoff, while the remaining
four did not signiﬁcantly differ. Comparing the expression level
variations between the two experiments showed HeLa cells having
a signiﬁcantly higher number of downregulated miRNAs than
Table 1 The most enriched canonical pathways associated
with the target genes of miRNAs modulated upon APE1-
silencing
Ingenuity canonical pathways −log(P-value) Ratio
Molecular mechanisms of cancer 8.39 0.12
Chronic myeloid leukemia signaling 6.61 0.18
Cardiac hypertrophy signaling 6.36 0.13
Glioma signaling 6.22 0.17
Estrogen-mediated S-phase entry 6.20 0.38
Glioblastoma multiforme signaling 5.96 0.15
IL-8 signaling 5.87 0.13
PPARa/RXRa activation 5.63 0.14
Endothelin-1 signaling 5.25 0.13
PEDF signaling 5.22 0.18
Myc-mediated apoptosis signaling 4.80 0.19
HGF signaling 4.69 0.15
Glucocorticoid receptor signaling 4.59 0.11
Pancreatic adenocarcinoma signaling 4.55 0.14
Hepatic ﬁbrosis/hepatic stellate cell activation 4.42 0.12
G-protein coupled receptor signaling 4.26 0.10
Role of NFAT in cardiac hypertrophy 4.11 0.12
Statistical signiﬁcance and the ratio of genes included in the pathway are shown. Target genes
prediction and pathway enrichment analysis were performed using IPA (see also Supplementary
Data File 1). APE1 apurinic/apyrimidinic endonuclease 1, HGF hepatocyte growth factor, IPA
Ingenuity Pathway Analysis, PEDF pigment epithelium-derived factor, NFAT nuclear factor of
activated T cells
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Fig. 2 APE1 binding to pri-miR-221/222. a Validation of APE1 binding to pri-miR-221 and pri-miR-222 in different human cancer cell lines. qRT-PCR of pri-
miRs bound by APE1 in different cell lines transfected with either empty vector or with a vector expressing APE1WT FLAG-tag protein. Data are presented
as fold percentage of the amount of immunoprecipitated pri-miR relative to that present in total input RNA. b Pri-miR-221 and pri-miR-222 expression
levels evaluated by qRT-PCR analysis of HeLa cell clones silenced for APE1 expression. Total RNA was extracted from HeLa cell clones stably transfected
with scrambled siRNA control (SCR), with an APE1 siRNA (siRNA) and reverse transcribed as described in the Methods section. Histograms show the
detected levels of pri-miR-221 and pri-miR-221 normalized to GAPDH levels. Asterisks represent a signiﬁcant difference with respect to control (SCR).
*P< 0.05, **P< 0.001, Student’s t-test. Right, western blotting analyses of HeLa cell clone extracts silenced for APE1 expression. c Pri-miR-221 and pri-miR-
222 expression levels evaluated by qRT-PCR analysis of different cell lines. Total RNA was extracted from HeLa, HCT-116, and MCF-7 cell lines transiently
silenced for APE1 and reverse transcribed. Histograms show the detected levels of pri-miR-221 and pri-miR-221 normalized to GAPDH levels. Asterisks
represent a signiﬁcant difference with respect to control (SCR). *P< 0.05, **P< 0.001, Student’s t-test. Bottom, representative western blotting analyses to
conﬁrm APE1 silencing in HeLa, HCT-116, and MCF-7 cells. Tubulin was used as loading control. d Mature miR-221 and miR-222 expression levels
evaluated by qRT-PCR analysis of HeLa cells silenced for APE1 expression. Total RNA was extracted from HeLa cell clones stably transfected with
scrambled siRNA control (SCR), with an APE1 siRNA (siRNA), and reverse transcribed. Histograms show the detected levels of miR-221 and miR-222
normalized to RNU44 levels. Asterisks represent a signiﬁcant difference with respect to control (SCR). *P< 0.05, **P< 0.001, Student’s t-test. e Mature
miR to pri-miR ratios in HeLa cells clones silenced for APE1 expression. Mature miR-221 and miR-222 were measured by qRT-PCR analysis, normalized
to RNU44, and expressed relative to GAPDH-normalized pri-miR-221/222. Asterisks represent a signiﬁcant difference with respect to control (SCR).
*P< 0.05, **P< 0.001, Student’s t-test
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found in HOS cells, with a median logFC expression 4-fold higher
than for HOS (−1.8 and −0.4, respectively) (Supplementary
Data File 1). We found two miRNAs that were downregulated in
both conditions (miR-494 and miR-1246), and two others that
were upregulated upon H2O2-treatment but were downregulated
after APE1 silencing (miR-30b-5p, miR-92b-3p).
Target gene prediction and pathway enrichment analysis for
the APE1-kd cells, performed using Ingenuity Pathway Analysis
(IPA; QIAGEN Bioinformatics), demonstrated signiﬁcant enrich-
ment for molecular pathways of cancer development associated
with miRNA dysregulation (Table 1 and Supplementary Data
File 1). To determine whether the downregulation of miRNAs
upon APE1 depletion affects mRNA expression, we compared the
cumulative changes for genes that are miRNA targets vs. those of
random sets of mRNAs. Gene expression data were obtained
from a previous investigation from our laboratory14. To correct
for bias in the random set, we performed 1000 comparisons in
which the log(fold change) values were randomly selected from
the whole data set, while maintaining the size of the original
distribution (Fig. 1b). Using both the Kolmogorov–Smirnov test
and Wilcoxon test, the Benjamini and Hochberg method (BH)
adjusted P-values were statistically signiﬁcant (with conﬁdence
level= 0.95, P< 6 × 10−30 and P= 0.0016, respectively; see
Methods for further details and Supplementary Data File 1 for
the miRNA target prediction table).
Overall, these results suggest a positive impact of APE1 protein
on speciﬁc miRNA expression levels, possibly acting on the early
processing events and allow identifying miR-221 as a candidate
for testing, as a “proof of concept”, the hypothesis that
APE1 regulates the expression of target genes involved in
chemoresistance.
Precursor forms of miR-221/222 are bound by APE1. We then
investigated the molecular mechanism of APE1-affecting miRNA
expression, focusing our attention on miR-221 and miR-222,
because they are correlated in a polycistronic cluster and relevant
for PTEN expression28, 29, 31. Due to the ability of APE1 to directly
bind structured RNA molecules11, 12 and the double-stranded
nature of pri-miRNAs, we ﬁrst tested the ability of APE1 to bind
the primary transcript (i.e., pri-miRNA) forms of these miRNAs,
by performing RNA immunoprecipitation (RIP)-analyses in dif-
ferent cancer cell lines (i.e., HeLa, MCF-7 and HCT-116) upon
transient transfection (Fig. 2a). To this end, cell lines were tran-
siently transfected with FLAG-tagged APE1 wild-type protein-
encoding plasmid and the immunoprecipitated RNA was analyzed
by qRT-PCR to assess the levels of each pri-miR-221/222 bound by
APE1. As shown in Fig. 2a, we efﬁciently immunoprecipitated both
pri-miRNAs in all cancer cell lines tested.
Considering the potential of APE1 to regulate miRNA
processing via enzymatic cleavage of RNA with secondary
structure11, 12, we investigated the role of APE1 in miR-221/222
processing efﬁciency. First, we checked if the pri-miR-221/222
expression level was affected by APE1-kd in either HeLa cell
clones with a stably transfected siRNA vector (Fig. 2b), or in cells
transiently transfected with a different APE1-speciﬁc siRNA
(Fig. 2c). In both cases, APE1 depletion was followed by an
increase in pri-miR-221/222 expression compared to control
siRNA. In accord with this result, HeLa cell clones re-expressing
wild-type APE1 via an siRNA-resistant mRNA13 had almost the
same level of the two pri-miR transcripts as the cell clone
expressing a scrambled vector (SCR) (Fig. 2b).
This increased expression of pri-miR-221/222 in APE1-
depleted cells suggested that the primary transcript forms might
accumulate due to impairment of the early steps of miRNA-
processing dependent on APE1. Therefore, we assessed if the
accumulation of the pri-miR-221/222 was paralleled by a decrease
in the expression of mature miR-221/222 upon APE1-silencing
(Fig. 2d). miR-222 was ~6-fold more abundant than miR-221 in
control (SCR) HeLa cells, which was signiﬁcantly decreased upon
APE1 silencing (siRNA). In the case of miR-221, the changes
were not statistically signiﬁcant. On the other hand, the amount
of each pri-miR was increased upon APE1 silencing, as shown
by the corresponding miR/pri-miR ratio (Fig. 2e). The APE1
role was conﬁrmed in APE1-ko mouse cells (CH12F3)32
(Supplementary Fig. 2). Altogether, these results indicate that,
although to a different extent possibly dependent on the absolute
miR expression levels, the pri-miR-221/222 processing is
compromised in APE1-depleted cells.
Inhibition of APE1 impairs miR-221/222 expression. To deﬁne
the role of APE1 in processing miR-221/miR-222 precursors, we
tested whether the endonuclease or the redox activities of the
protein were involved. For this purpose, we treated HeLa cells
with different inhibitors of speciﬁc APE1 functions: (i) compound
#3, a catalytic inhibitor of APE1 endonuclease activity33;
(ii) ﬁduxosin, a recently characterized inhibitor of the APE1/
NPM1 interaction34, which localizes and activates APE1 function
in nuclear BER16. Thus, ﬁduxosin inhibits the protein endonu-
clease activity in cells through a mechanism that is different from
that of compound #3, but having a similar extent34; (iii) E3330, a
well-known inhibitor of APE1 redox activity now used in
clinical trials35, 36. Cells were challenged with all these
APE1 inhibitors for 24 h, and the miR-221/222 precursor and
mature forms were quantiﬁed through qRT-PCR (Fig. 3a).
Time and doses of treatments were chosen based on their effect
on cell viability and previous published data34, 37. The
interference with APE1 endonuclease activity by compound #3
and ﬁduxosin resulted in an accumulation of pri-miR-221
and pri-miR-222 (Fig. 3a). Conversely, the redox-inhibitor
exerted only a slight increase in the amount of mature miR-222.
Inhibition of APE1 endonuclease activity was demonstrated
by in vitro cleavage assays using a substrate bearing an AP
site (Fig. 3a and Supplementary Fig. 3a). Of note, the impaired
miRNA processing observed upon APE1 endonuclease inhibition
was not associated with any effect on the total amount of APE1
protein (Supplementary Fig. 3b).
To complement the inhibitor experiments, we expressed
mutant APE1 proteins with different defects in APE1-kd
cells. These included a nuclease-defective form (APE1E96A)38, a
redox-defective form (APE1C65S)39, and a protein lacking
the N-terminal 33 residues (APE1NΔ33) which does not
interact with NPM113, 40. These proteins were expressed at
comparable levels, while endogenous APE1 was mostly sup-
pressed (Fig. 3b).
The results with the mutant APE1 proteins (Fig. 3b) supported
the conclusion that the endonuclease function of APE1 and its
N-terminal region are essential for the normal processing of
pri-miR-221/222. In contrast, the redox-defective APE1C65S
showed a small increase of miR-222 mature form relative to the
precursor, which may be explained by secondary effects due to
the expression of this mutant in HeLa cells, as we previously
described41. Notably, since the APE1NΔ33 lacks critical localiza-
tion signals and has impaired interactions with other proteins
besides a reduced interaction with NPM114, we cannot exclude
that both regulatory aspects could participate in the cellular
endpoints measured.
In the OCI/AML3 cell line that stably expresses the aberrantly
cytoplasmic NPMc+ mutant protein, APE1 is also mis-localized
to the cytoplasm, which impairs nuclear BER16. In these cells, we
observed an increased accumulation of pri-miR-221/222 (Fig. 3c)
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compared to cells with wild-type NPM1. Such an effect was
previously reported without a molecular explanation of the
results27. These data paralleled those obtained with ﬁduxosin34
indicating that NPM1 exerts a positive effect on APE1 pri-
miRNA-processing activity. As APE1 depletion impaired proces-
sing of pri-miR-221 and pri-miR-222, we also tested if APE1
overexpression would give the opposite effect (Fig. 3d). HeLa cells
were transfected with a plasmid encoding the APE1–FLAG-
tagged protein, and the ratio of mature miR to pri-miR was
evaluated. The absence of a statistically signiﬁcant effect, suggests
that other proteins may be the rate-limiting factors in the pri-miR
processing pathway.
Overall, our data show that the endoribonuclease activity
of APE1 appears required for the early phases of miR-221/222
processing but that additional protein factors may also play
a role.
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APE1 interaction with DROSHA is enhanced by genotoxic
damage. APE1-deﬁciency leads to increased RNA oxidation13.
We thus speculated that the APE1 requirement in pri-miR-221/
222 processing could reﬂect an action of APE1 on RNA-decay
pathways for pri-miRNAs, possibly associated with the DROSHA
microprocessor complex. A possible interaction between APE1
and the DROSHA microprocessor complex was tested using the
proximity ligation assay (PLA) in HeLa cells under oxidative
stress conditions, which may modulate their interaction. The
results in Fig. 4a point to an interaction between APE1 and
DROSHA in the nucleoplasmic compartment, where pri-miRNAs
are processed under normal conditions. Speciﬁcity was demon-
strated by the reduced number of PLA spots in a negative control
omitting the antibody for DROSHA; as a positive control for an
APE1-interacting partner, we conﬁrmed the known interaction
between APE1 and NPM116, 42 (Supplementary Fig. 4a).
Moreover, the lack of detectable interaction between APE1 and
the essential microprocessor complex component DGCR8
(DiGeorge critical region 8) or with the auxiliary factor DEAD-
box RNA helicase p68 (DDX5) is consistent with a role of APE1
in the early phase of microprocessor pathways (Supplementary
Fig. 4b). The APE1/DROSHA interaction was stimulated by
H2O2 at very early times upon treatment, peaking at 15 min of
treatment with 1 mM H2O2, thus supporting the hypothesis for a
role of APE1 in the quality control of oxidized RNA10. As
expected, the H2O2-induced PLA-signal was greatly reduced in
APE1-kd cells compared to cells with the control siRNA (Sup-
plementary Fig. 4c, d). The role of APE1 seems to extend to RNA
damaged by non-oxidative agents: treatment with the alkylating
compound MMS also stimulated the APE1/DROSHA interaction,
though less dramatically than did H2O2 treatment (Supplemen-
tary Fig. 4e).
The interaction between APE1 and DROSHA seems
transitory. We were unable to detect any signiﬁcant interaction
between these proteins by Co-IP in experiments whereas the
known APE1–NPM1 interaction13, 42 was easily detected
(Supplementary Fig. 4f). This observation was predictable, since
the interaction implies the enzymatic activities of two proteins
(i.e., APE1 and DROSHA) on RNA molecules with high turnover
rates. Alternatively, it may be that the APE1–DROSHA interac-
tion occurs on an RNA molecule that can be degraded during the
co-immunoprecipitation (Co-IP) procedure.
Inspecting the pri-miR-221/222 expression levels after a 15 min
treatment with 1 mM H2O2, we observed a time-dependent
increase in the levels of both pri-miRs, with respect to untreated
(NT) cells (Fig. 4b). This effect was more pronounced for
pri-miR-221. However, this oxidant-induced increase did not
correlate with an increase in the mature miRNA forms, as seen in
the kinetics of the miR:pri-miR-221/222 ratio (Fig. 4b). This is
possibly due to a blockage in the maturation process during
oxidative stress under this experimental condition (Fig. 4b). The
different kinetics observed in the case of the two miRNAs,
particularly once starting the release time upon H2O2-treatment
(indicated as time 0 of release), may be ascribed to a different
turnover rate of the two miRNAs.
Finally, as APE1 may be involved in the turnover of damaged
pri-miRNAs, we measured the extent of oxidative base loss in
pri-miRNA-221/222 as a function of APE1 expression using
an aldehyde-reactive probe (ARP)43. Indeed, APE1-kd was
associated with a signiﬁcant increase in damage to both
pri-miRNAs, with re-expression of wild-type APE1 eliminating
this effect (Fig. 4c). We thus hypothesize an unanticipated
function of APE1 in the microprocessor complex, possibly
associated with pri-miRNA-decay mechanisms and affecting the
miRNA maturation processes during genotoxic damage.
APE1 effect on PTEN-pathway correlates with miR-221/222.
We tested the functional relevance of our ﬁndings on the biolo-
gical targets of miR-221/222 by examining the expression of
PTEN, a tumor suppressor protein known to be functionally
related to APE1 expression6. The effect of both APE1 silencing
(Fig. 5a) and inhibition (Fig. 5b) were assessed for PTEN mRNA
and protein levels. qRT-PCR and western blotting analyses
revealed upregulation of PTEN in APE1-kd cells or in cells
treated with compound #3, with a concomitant downregulation
of the miR/pri-miR-221/222 ratios. As PTEN negatively regulates
the AKT pathway by antagonizing PI3K activity by depho-
sphorylating PIP328, we evaluated the phosphorylation of Akt
(p-AKT) in APE1-kd cells. Consistent with PTEN upregulation
under APE1 silencing, there was a decrease in p-AKT phos-
phorylation (Fig. 5c). Conversely, APE1 overexpression caused a
partial rescue of p-AKT phosphorylation (Fig. 5c). The effect of
APE1 on PTEN expression may be linked to the action of the
former in miRNAs processing.
Correlations of APE1 and miR-221/222 with PTENs in cancer
specimens. To determine the signiﬁcance for human cancer of
the correlation between APE1 and miR-221/222 processing
PTEN expression, we analyzed a cohort of 94 tissue samples from
chemotherapy-naive and radiotherapy-naive patients diagnosed
with colorectal cancer, glioblastoma, breast cancer, cervical
Fig. 3 Inhibition of APE1 endonuclease activity negatively affects miR-221 and miR-222 processing. a Mature miR-221 and miR-222 were measured by
qRT-PCR in HeLa cells treated with 20 µM compound #3, 40 µM ﬁduxosin (FDX) and 100 µM E3330 for 24 h, respectively. Mature miRNAs were
normalized to RNU44 and expressed relative to GAPDH-normalized pri-miR-221/222. Right, AP-site incision activity of total cell extracts from HeLa cells
treated with the indicated APE1 inhibitors or HeLa cells silenced for APE1 (siRNA). siRNA cell extracts were used as negative control. The histogram
indicates the percentage conversion of an AP site-containing DNA substrate (S) to the incised product (P). Data are expressed as mean± SD of three
technical replicates from two independent assays. A representative image of the denaturing polyacrylamide gel of the enzymatic reactions is shown. NE no
cell extract, NT non-treated cells. Asterisks represent a signiﬁcant difference with respect to control (NT).*P< 0.05, **P< 0.001, Student’s t-test. b Mature
miR to pri-miR ratios in HeLa cell clones silenced for the endogenous APE1 expression and transiently transfected with expression plasmids for FLAG-
tagged, siRNA-resistant APE1 mutants APE1WT, APE1NΔ33, APE1E96A, and APE1C65S. Mature miR-221 and miR-222 levels were measured by qRT-PCR
analysis, normalized to RNU44, and expressed as relative to GAPDH-normalized pri-miR-221/222. Asterisks represent a signiﬁcant difference with respect
to control (SCR). *P< 0.05, **P< 0.001, Student’s t-test. Below, western blotting analysis showing HeLa cell clones silenced for endogenous APE1–protein
(endo) and re-expressing ectopic APE1–FLAG-tagged mutants (ecto). c miR-221 and miR-222 expression levels evaluated by qRT-PCR analysis of
OCI/AML-2 and AML-3 cells lines. OCI/AML2 cells represent the control expressing a wild-type NPM1 protein, which accumulates within nucleoplasm
and nucleoli. Histograms show the ratio between mature miRNAs relative to their GAPDH-normalized precursors. Asterisks represent a signiﬁcant
difference with respect to control (OCI/AML-2).*P< 0.05, **P< 0.001, Student’s t-test. d miR-221 and miR-222 expression levels evaluated by
qRT-PCR analysis of HeLa cells overexpressing APE1 by transient transfection of APE1–FLAG-expressing plasmid. Histograms show the ratio
between mature miRNAs relative to their GAPDH-normalized precursors. Below, western blotting analysis showing HeLa cells transfected with
ectopic APE1 FLAG-tagged plasmid
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cancer, and non-small cell lung cancer (NSCLC). APE1 and
PTEN protein expression were estimated by immunohistochem-
istry (IHC), and representative images of APE1-high and
APE1-low examples for the ﬁve cancer types are shown in Fig. 6a.
Statistical analysis shows a trend with higher PTEN-high
expression in samples scored as “APE1-low” (r= −0.665,
P< 0.0001 Student’s t-test), consistent with the in vitro studies.
Both the mature and the primary forms of miR-221/222 were
quantiﬁed using qRT-PCR, and the corresponding miR/pri-miR
ratios were calculated (Fig. 6c, d). As shown in the scatter plots,
more samples with a high ratio of mature/primary miR-221/222
were associated with higher APE1–protein levels. Statistical
analyses further indicated APE1 correlation with miR-221/222
processing (miR-221: r= 0.92, P< 0.0001; miR-222: r= −0.649,
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P< 0.0001 Student’s t-test). APE1–protein level was inversely
correlated with pri-miR-221/222 (pri-miR-221: r= −0.491,
P< 0.0001 and pri-miR-222: r= −0.497, P< 0.0001 Student’s
t-test), and with mature miR-221/222 (miR-221: r= 0.343,
P< 0.0001 and miR-222: r= 0.418, P< 0.0001 Student’s t-test).
Taken together, the relationship between APE1 and miR-221/222
processing, and with PTEN expression, was validated in clinical
tumor samples, supporting the hypothesis that the observed
mechanism is bona ﬁde a general effect in cancer.
APE1–protein interactome network dynamics. The role of
APE1 in miRNA processing and its role during genotoxic damage
highlight a central function of this protein in RNA metabolism.
Therefore, we speculated that APE1 may be a hub involved
in a dynamic interaction with many proteins involved in
RNA-processing/metabolism as we already observed10, 13. To
experimentally test this hypothesis, we ﬁrst implemented the
number of known APE1-interacting partners by using proteomic
analysis of APE1 co-immunopuriﬁed material3, 13, 14 obtained
from whole-cell extracts. This was done with the aim to avoid
possible artifacts due to subcellular fractionation procedures and
to have a representative interactomic network considering the
relative abundance of the different protein species. In this
analysis, we took also into account the role of acetylation
in modulating the APE1-interactome, because of recent publica-
tions demonstrating its association with cancer44, 45 and for the
fact that acetylation is responsible for modulating
APE1 subcellular distribution42 and RNA-binding properties17, 40
(Supplementary Note, Supplementary Fig. 5a–e, and Supple-
mentary Data Files 2–5). Overall, the APE1-interactome network,
characterized in part in our laboratory and in different literature
works, actually comprises 103 different protein species including
the newly identiﬁed ones (Supplementary Data Files 2 and 6).
When we functionally annotated this list using IPA, we observed
that the majority (93%) of APE1-binding partners were related to
ﬁve biological pathways and, in particular, 63% of them were
linked to processing of RNA (e.g., YB-1, NPM1, RPLP0, NCL,
PRPF19), DNA repair (e.g., LIG1, POLB, XRCC1, OGG1, FEN1),
and gene expression (e.g., STAT3, NME1, MDM2, TCEB1,
POLR3D) (Fig. 7a, b; Supplementary Fig. 6a, b and Supplemen-
tary Data File 6).
Moreover, we found that APE1 may undergo acetylation in
several residues (i.e., Lys3/6/7/27/31/32/35/141/197/203/227/228)
mainly located in the unstructured N-terminus (Supplementary
Fig. 5a; and Supplementary Data Files 3 and 4), conﬁrming our
previous40 and literature studies45, and that acetylation of APE1
is associated to a modulation of its protein interactome network
(Supplementary Fig. 5c, d and Supplementary Data Files 3 and 4).
Interestingly, the APE1–protein interactome was mediated by
RNA molecules. In fact, treatment of immunoprecipitated
material with DNase I-free chromatographically puriﬁed RNase
A mostly reduced the interaction of APE1 with the different
interacting proteins, while DNase I-treatment was almost
ineffective (Supplementary Fig. 7a). Altogether, these data clearly
demonstrate that the APE1–protein interactome network is
largely mediated by RNA and is dynamically modulated by
acetylation and during genotoxic conditions. Moreover, these
ﬁndings reinforce the idea that APE1 may act as a multifunctional
hub protein, emphasizing the emerging role that APE1 plays in
RNA metabolism and the relevance of its protein interactome
once considering the many different activities ascribed to this
protein in cancer.
Genome-wide identiﬁcation of the APE1–RNA-interactome
network. Based on the observation that RNA contributes to
the APE1–protein interactome and that APE1 directly binds
pri-miRNAs and rRNA13, 40, we then used an unbiased approach
to investigate the associations of APE1 with non-ribosomal RNA
species using modiﬁed RIP-seq analysis. RNA-bound APE1,
extracted from HeLa cell clones expressing an ectopic FLAG-
tagged wild-type APE1–protein, was puriﬁed using an anti-FLAG
antibody whose speciﬁcity was already well-characterized in
previous IP-studies2 (Supplementary Fig. 8a). Three independent
immunoprecipitation experiments were performed; to further
reduce potential false positives, a negative control of resin
lacking the proper antibody was also introduced. Input samples
for each triplicates were also collected and sequenced. Co-IP
Western blot analyses conﬁrmed that FLAG-APE1 was efﬁciently
afﬁnity puriﬁed exclusively from HeLa cell extracts immunopre-
cipitated with the resin carrying the anti-FLAG antibody
(Supplementary Fig. 8b). RNA bound by APE1 was then sub-
jected to sequencing analysis and bound transcripts were identi-
ﬁed. We obtained an average of 38.84 and 34.23 million reads for
the libraries from RIP control cells and APE1-overexpressing
HeLa cells, respectively. Among the 1015 RNA molecules, in
addition to 989 protein coding genes, we found 26 non-coding
elements (2 lincRNAs, 2 ncRNAs, 5 antisense RNAs, 8 pseudo-
genes, 8 processed transcripts, and 1 miRNA) (Supplementary
Data File 7). Since our RNA-seq analyses was not optimized for
miRNA/pri-miRNA sequencing, we cannot actually exclude that
additional miRNAs/pri-miRNAs could be bound by APE1, as we
here demonstrated (Fig. 2a). In order to validate RIP-seq results,
among the 1015 predicted RNAs bound by APE1, some
RNA targets were also evaluated through qRT-PCR analysis
(Supplementary Fig. 8c).
To determine the functions of the APE1-associated-RNA genes
(AARGs) by a more global analysis, we investigated for their
molecular functions using the Core Analysis function included in
IPA. After the analysis, biofunctions and diseases were ordered by
the statistical signiﬁcance score (−log P-value). The top ﬁve
functional annotation clusters of AARGs, considering the
biofunctions, are shown in Fig. 8 (see also Supplementary Data
File 7). Interestingly, this analysis revealed that the AARGs are
mostly involved in RNA-metabolism (transcription, processing,
Fig. 4 Interaction of APE1 with the DROSHA complex is stimulated by oxidative stress. a Nucleoplasmic interaction between APE1 and the DROSHA
complex after oxidative stress. HeLa cells were placed on a glass coverslip and treated with 1 mM H2O2 for 15, 30, and 60min. PLA reaction was carried
out using anti-APE1 and anti-DROSHA antibodies. APE1 expression was detected by using an anti-APE1 antibody and was used as a reference for the
nuclei. Data reported in the histogram account for the average number of PLA signals of at least 30 randomly selected cells per condition. **P< 0.001,
Student’s t-test. b miR-221 and miR-222 expression levels evaluated by qRT-PCR analysis of HeLa cells treated with 1 mM H2O2 for 15 min and released for
1, 3 or 6 h after treatment. Histograms show the detected levels of pri-miR-221 and pri-miR-221 normalized to GAPDH levels (left) and the ratio
between mature miRNAs relative to their GAPDH-normalized precursors (right). Asterisks represent a signiﬁcant difference with respect to control (NT).
NT non-treated. *P< 0.05, **P< 0.001, Student’s t-test. c Total RNA, isolated from HeLa cell clones, was reacted with aldehyde-reactive probe speciﬁcally
on oxidative abasic sites, followed by precipitation with magnetic beads. Precipitated oxidized RNA and total RNA were subjected to qRT-PCR individually
using TaqMan probe for pri-miR-221 or pri-miR-222. Oxidation levels of miRNAs were determined based on difference in Ct value between oxidized and
total RNA. Data are represented as mean± SD after three replication tests. *P< 0.05, Student’s t-test
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splicing, and oxidation of RNA), supporting our previous
hypothesis on the crucial role exerted by APE1 in RNA
biology10–13. We obtained similar results using DAVID/EASE
enrichment analysis46 (Supplementary Fig. 8d and Supplementary
Data File 7). Interestingly, enrichment of AARGs involved in DNA
metabolism as well as organization of cytoskeleton and organelles
may suggest a potential role of APE1 in RNA-trafﬁcking or
RNA-processing events. Moreover, the analysis of diseases clearly
showed a central role of APE1–RNA-bound species in various
types of cancer (Table 2 and Supplementary Data File 7). Taken
together, these analyses show that APE1 binds a highly coherent
set of RNA targets, closely related to its roles in both normal
biology and disease. Moreover, these ﬁndings strongly suggest that
one important mechanism, through which APE1 may regulate
gene expression, is by directly acting on RNA molecules, possibly
through RNA-processing/decay events and involving different
protein complexes.
Discussion
Here, we demonstrated that the BER enzyme APE1 may represent a
new hub in RNA-processing events, including miRNA regulation,
thus post-transcriptionally affecting gene expression with relevance
in chemoresistance. Its association with a network of RNA and
protein species, highly related to its functions, opens new
perspectives for understanding the multifunctional roles of this
unusual DNA-repair enzyme. To the best of our knowledge, this
investigation reveals a previously unpredicted function of APE1 in
miRNA processing, which may underlie novel key aspects of APE1
in cancer biology. Interestingly, we found that APE1, through direct
interaction with the DROSHA microprocessor complex, enhances
the post-transcriptional maturation of miR-221/222, thus impacting
on PTEN gene expression and affecting the Akt pathway under
basal conditions. The observation that oxidative or alkylating agents
promote APE1/DROSHA interaction and that APE1-kd is
associated to increased oxidation levels of pri-miRNAs would
support a major role of APE1 in the RNA-decay mechanisms of
miRNA primary transcripts. Considering our previous data on
APE1 endoribonuclease activity over abasic and oxidized RNA13,
the model described here could be generalized to the majority of
oxidative stress-regulated miRNAs and possibly extended to all
RNAs which undergo extensive damage including oxidation, alky-
lation and abasic lesions formation19. Interestingly, oxidative
modiﬁcation of mRNA seems to be highly selective, having an
impact on the expression level of speciﬁc genes and on protein
translation efﬁciency24, 47. Alterations of these pathways have a role
in the pathogenesis of different human pathologies ranging from
ageing to neurodegenerative and cancer diseases22, 48, 49.
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Fig. 5 Impact of miR-221/222 processing on PTEN protein expression. a PTEN mRNA levels evaluated by qRT-PCR analysis of HeLa cell clones silenced for
APE1 expression. Total RNA was extracted from HeLa cell clones expressing APE1 WT or APE1 silenced (siRNA) and reverse transcribed. Histogram
shows the detected levels of PTEN normalized to GAPDH levels. Asterisks represent a signiﬁcant difference with respect to control (SCR).*P< 0.05,
Student’s t-test. b PTEN mRNA levels evaluated by qRT-PCR analysis of HeLa cell treated with 20 µM compound #3 or 100 µM E3330 for 24 h,
respectively. Histogram shows the detected levels of PTEN normalized to GAPDH levels. Asterisks represent a signiﬁcant difference with respect to control
(NT). **P< 0.001, Student’s t-test. c PTEN protein level evaluated in HeLa cell clone silenced for APE1 expression. Representative western blotting analyses
of total cell extracts of HeLa cell clones. PTEN expression inversely correlates with phosphorylation of Akt1 (pAkt1). Histogram reports expression level of
PTEN and pAkt protein obtained after quantiﬁcation of the signal intensity of the corresponding bands. Data represent the means of± SD of three
independent experiments. Tubulin was used as loading control and for data normalization. Asterisks represent a signiﬁcant difference with respect to
control (SCR).*P< 0.05, **P< 0.001, Student’s t-test
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Wang et al. recently demonstrated that also miRNAs can be
oxidatively modiﬁed by ROS, changing their binding properties
from native targets to new ones, as in the case of miR-18425. It is
worth noting that the duplex structure of pri-miRNAs precursor
may represent the favorite target of APE1 activity17. Therefore, we
should reinterpret the roles of APE1 in modulating cellular
responses to genotoxic stresses and in the pathogenesis of human
diseases, in light of the new role of this multifunctional protein in
RNA biology.
miR-221 and miR-222 are two highly homologous miRNAs,
tandemly encoded on the X-chromosome, whose overexpression
has been recently described in several human malignancies,
including thyroid papillary carcinomas, glioblastoma, prostate
carcinoma, gastric carcinoma and others50. They both act as
oncogenic miRNAs commonly targeting a cluster of genes with a
key role in tumor inhibition, such as PTEN in tumor suppression,
PUMA in apoptosis, TRPS1 in epithelial to mesenchymal transi-
tion and the cell cycle inhibitors p27Kip1 and CDKN1C/p57 50, 51.
Upregulation of miR-221/222 has been shown to confer radio-
resistance, cell growth and invasion capabilities to different cancer
cell types by suppressing the action of PTEN and their other
critical target29, 31, 52, 53. Furthermore, upregulation of miR-221/
222 has been associated with the development of multidrug
resistance and altered response to chemotherapy54–56. Therefore,
restoring these anti-cancer genes expression by inhibiting
miR-221/222 levels has been considered as a potential therapeutic
strategy50. Interestingly, we noticed that the different pri-miR-221
and pri-miR-222 expression levels we measured, may be sugges-
tive for independent expression by different promoters, as also
conﬁrmed by experimental data obtained from the FANTOM5
project57. In fact, in the 1174 human samples analyzed, the
RLE-normalized promoter activity of miR-222 is on average
3.8-fold higher than that of miR-221. Therefore, in addition to a
commonly thought polycistronic nature, miR-221 and miR-222
may be independently transcribed (Supplementary Fig. 9).
Regarding the critical role of apoptosis-resistance and EMT in
acquired resistance to radiotherapy, chemotherapy, and targeted
therapy, our result that APE1-endonuclease activity can interfere
with miR-221/222 biogenesis represents, to the best of our
knowledge, a novel combinational therapeutic approach via using
APE1 inhibitors to enhance efﬁcacy of current cancer treatment.
PTEN is a well-known tumor suppressor gene that negatively
regulates the major cell survival PI3K/AKT signaling pathway.
Downregulation of PTEN, as a consequence of miR-221/222
overexpression, results in a constitutive activation of the PI3K/
AKT pathway, which in turn promotes cell transformation58–60.
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Fig. 6 Correlative expression of APE1 and miR-221/222 with PTEN in a cohort of human cancer specimens. a APE1 and PTEN protein expression were
determined by IHC assay and the representative images of both APE1 and PTEN were shown. PTEN expression signiﬁcantly increased in tumor tissues
showing poor APE1 expression, while was suppressed in tumor tissues showing high APE1 expression. b Bar graph showing the percentage of each score
level of PTEN in 0, 1, 2, and 3 score level of APE1. Data were categorized as follow: (i) score 0, no expression in tumor cells; (ii) score 1, faint/barely
perceptible partial expression in <10% of tumor cells; (iii) score 2, weak to moderate expression in >10% of tumor cells; (iv) score 3, strong expression in
>10% of tumor cells. c and d Scattered plots showing distribution of miR to pri-miR ratios for miR-221 and miR-222 in each score level of APE1–protein
staining, respectively
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Fig. 7 APE1–protein interactome network. a Protein network generated by Ingenuity Pathway Analysis. Starting from the gene list of the APE1-interacting
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These ﬁndings parallel our previous data6, in which we observed
that APE1 silencing, while blocking the Egr-1 mediated inducible
expression of PTEN gene upon H2O2 or TSA treatments, was
associated with a paradoxical upregulation of the PTEN protein
itself under basal condition. Now, we propose a model in which
APE1 acts as a central player in the homeostatic regulation
of PTEN expression through transcriptional (via Egr-1) and
post-transcriptional (via miR-221/22) counteracting mechanisms
involved in a feedback autoregulatory loop. This model could be
generalized to a number of genes regulated by APE1,
whose expression was previously considered a sort of paradox3, 6.
These observations are also of particular interest for cancer
development, in light of recent papers in which APE1 expression
has been correlated with low-PTEN expression in high grade
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Fig. 8 RIP identiﬁcation of RNAs interacting with APE1. Top-ﬁve functional annotation clusters of APE1–RNA targets identiﬁed by Ingenuity Pathway
Analysis based on functional terms of the “Biological Process” category. RNAs in more than one cluster are cross-referenced with numbers
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gliomas with poor prognosis61. Our conﬁrmation, in a cohort of
different tumors, that the expression of APE1 correlates with that
of mature miR-221/222, and inversely with that of PTEN,
reinforces the relevance of our hypothesis in human cancer.
Interestingly, miR-221/222 were recently found to be post-tran-
scriptionally dysregulated in AML patients27, in which also the
APE1-endonuclease function is impaired16. Thus, our data
highlight an unexpected new mechanism through which APE1
overexpression may play a central role in chemoresistance
through post-transcriptional mechanisms involving onco-miR-
NAs regulation and onco-miRNAs decay; these ﬁndings may
open new perspectives for cancer diagnosis and therapy.
Intimate cross-talks between miRNA-processing machineries
and nuclear factors is an emerging ﬁeld of study in the DDR
pathways, which may reveal important aspects of regulation in
cancer biology62–64. Under genotoxic stress conditions, acetylated
p53 can control the transcription and processing of some
pri-miRNAs through association with p68 (DDX5), an RNA
helicase of the DROSHA microprocessor complex65. Since APE1
acts as a regulator and interacting partner of p5366 and it is able
to bind some pri-miRNAs65, we may speculate that APE1
endoribonuclease activity is a part of the inducible mechanisms
regulating the processing of speciﬁc pri-miRNAs, during DDR
due to oxidative stress and alkylating treatment. In this context,
APE1 should control the quality of the precursor pre-miRNAs in
the nucleus during miRNA biogenesis. Several modulators have
been reported to inﬂuence the processing of pri-miRNAs besides
p68 and p53, such as p72/p82 (DDX17), ADAR1, hnRNP A1,
KSRP, SMADs, BRCA, YAP, Lin28, mutp53, DDX1, ARS2, DR5,
ERα, and ERβ64. Notably, a recent work demonstrated that an
APE1-interacting protein, i.e., YB-1, regulates the biogenesis of
miR-29b-2 by blocking the recruitment of the microprocessor
complex and Dicer to its precursor, and upregulates the expres-
sion levels of the host transcripts of miR-221/22267. These results
are suggestive that our novel ﬁndings on APE1, to the best of
our knowledge, may delineate new fascinating perspectives in
miRNA biology.
Remarkably, APE1 may have a general role in RNA processing,
not limited to miRNAs regulation. Through RIP-seq analyses,
more than 1000 transcripts were found to be bound by APE1;
they have functional involvement in RNA processing, regulation
of transcription, and DNA repair with profound relevance in
cancer development. This result provides a deﬁnitive evidence on
APE1 participation in many pathways through post-transcrip-
tional mechanisms10–13. By using microarray analyses on
HeLa cells as a cancer cell model, we previously demonstrated
that APE1 silencing is associated with profound changes in
gene expression14. Comparison of these data with previous
gene expression proﬁling of APE1-kd cells14 highlighted that
the majority of APE1-regulated genes are potential target of
APE1-regulated miRNAs (Supplementary Data File 1) suggesting
that a signiﬁcant portion of APE1-target genes may be regulated
through indirect mechanisms involving non-coding RNAs. This
ability to regulate gene expression through non-coding RNAs will
increase our understanding of the biological functions of APE1,
thus providing novel basis for the use of APE1 as a druggable
target for cancer therapy. Although additional molecular details
need to be delineated, our discovery that APE1 is a novel player in
miRNAs biogenesis opens a new scenario in the study of this
fascinating multifunctional protein.
Methods
Cell lines and materials. HeLa, HCT-116 (ATCC, Manassas, VA), and MCF-7 cell
lines (Sigma-Aldrich, St. Louis, MO) were grown in Dulbecco's modiﬁed Eagle's
medium (Invitrogen, Monza, Italy) supplemented with 10% fetal bovine serum
(Euroclone, Milan, Italy), 100 Uml−1 penicillin, 10 μg ml−1 streptomycin sulphate.
OCI/AML-2 and OCI/AML-3 cell lines (a kind gift by Emanuela Colombo)
were grown in alpha-MEM (Euroclone) supplemented with 20% fetal bovine
serum, 100 Uml−1 penicillin and 10 μg ml−1 streptomycin sulfate. HeLa cell clones
expressing an ectopic APE1–FLAG-tagged form13 were grown in Dulbecco's
modiﬁed Eagle's medium supplemented with 10% fetal bovine serum, 100 Uml−1
penicillin, 10 μg ml−1 streptomycin sulfate, 3 μg ml−1 blasticidin, 100 μg ml−1
zeocine, and 400 μg ml−1 geneticin (Invitrogen, Carlsbad, CA). For inducible
APE1-shRNA experiments, doxycycline (1 μg ml−1; Sigma-Aldrich) was added
to the cell culture medium, and cells were grown for 10 days, as previously
described13, 14. All cell lines were tested and free of mycoplasma contamination
(N-GARDE Mycoplasma PCR Reagent, Euroclone).
Transient transfections and cellular treatments. One day before transfection,
cells were seeded in 10-cm plates at a density of 3 × 106 cells per plate. Cells were
then transiently transfected with 6 µg of plasmidic DNA using Lipofectamine 2000
Reagent (Invitrogen) according to the manufacturer’s instructions and collected
24 h after transfection. APE1-kd HeLa cells were transiently transfected with
expression plasmids for FLAG-tagged, siRNA-resistant APE1 mutants APE1WT,
APE1NΔ33, APE1E96A, and APE1C65S which bears two mismatches in the cDNA
sequence preventing the degradation of the ectopic APE1 mRNA, while leaving the
APE1 amino acid sequence unaffected and with an empty-plasmid as a control.
For siRNA experiments, cell lines were transfected with 100 pmol siRNA
APE1 5ʹ-UACUCCAGUCGUACCAGACCU-3ʹ or the scramble control siRNA
5ʹ-CCAUGAGGUCAUGGUCUGdTdT-3ʹ (Dharmacon, Lafayette, CO) using
Table 2 The most enriched functional annotation disease clusters of APE1–RNA targets identiﬁed by Ingenuity Pathway Analysis
Diseases P-value Score # Molecules
Cancer Epithelial cancer 1.11E−23 22.95 756
Digestive system cancer 6.91E−20 19.16 701
Colon cancer 3.46E−10 9.46 393
Breast cancer 1.15E−05 4.94 158
Ovarian cancer 2.78E−04 3.56 121
Hematologic cancer 1.16E−03 2.94 209
Hematological Anemia 8.72E−06 5.06 39
High risk myelodysplastic syndrome 2.63E−04 3.58 3
Lymphoproliferative disorder 4.37E−04 3.36 203
Neurological Spinocerebellar ataxia 1.92E−04 3.72 13
Disorder of basal ganglia 5.47E−04 3.26 64
Early stage Alzheimer's disease 6.37E−04 3.20 3
Neural tube defect 6.36E−05 4.20 19
Movement disorders 1.55E−04 3.81 89
Degeneration of nervous system 5.64E−04 3.25 29
Behaviour Autistic-like traits 1.66E−03 2.78 2
P-value, enrichment score and number of molecules for each speciﬁc term are shown. APE1 apurinic/apyrimidinic endonuclease 1
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DharmaFECT reagent (Dharmacon). After 72 h upon transfection, cells were
collected and RNA extracted.
For APE1 endonuclease activity inhibition, HeLa cells were treated with 20 µM
APE1 endonuclease inhibitor #333, 40 µM of ﬁduxosin34, and 100 µM of E333035, 68
for the indicated time.
NanoString nCounter system miRNA Assay. miRNA expression proﬁling was
performed with 100 ng of total RNAs form HeLa cell clones silenced for
APE1–protein expression. RNA was isolated using the miRNeasy kit (Qiagen,
USA) and samples were prepared for nCounter miRNA expression proﬁling
using the human v2 miRNA expression panel, according to the manufacturer’s
recommendations (NanoString, Seattle, Washington, USA) in the Geneticlab Srl.
Transcript counts were normalized through the normalization method incorpo-
rated in the model framework, estimating parameters from positive controls,
negative controls, and housekeeping genes embedded in the nCounter system,
using the NanoStringDiff package within Bioconductor69. Differential expression
of genes was assessed on log2-normalized data with a generalized linear model
likelihood ratio test, using the glm.LRT function within the NanoStringDiff
package. A q-value cutoff of 0.1 was used to determine statistical signiﬁcance. For
clustering analysis, raw values were normalized using the NanoStringNorm
package70. Starting from the log2-normalized values, genes with low standard
deviation (SD< 0.2) were ﬁltered out and hierarchical clustering of the samples
was performed using Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/
software.htm). The quality of the data was checked by the mean expression and SD
values for housekeeping miRNAs and positive/negative controls (Supplementary
Fig. 1c). Visualization of the clustering and of the heatmap of log2-normalized
values were obtained using Java Treeview71. Independent validation analysis on
10 differential miRNAs was performed through qRT-PCR.
Cumulative distribution function plot analysis. The data set E-MEXP-131514,
which was retrieved from Array-Express, was used to evaluate the differential gene
expression between APE1-depleted and control cells. Standard procedures were
used to obtain the log fold change for all the genes present in the microarray.
Brieﬂy, CEL ﬁles were loaded with Affy package, and Robust Multi-Array Average
normalization was applied72. Statistical analysis for differentially expressed genes
was performed with a linear model regression method using the Limma package73.
P-values were adjusted for multiple testing using the Benjamini and Hochberg’s
method to control the false discovery rate74. Gene annotation was obtained
from R-Bioconductor metadata packages, and the probesets were converted in
Entrez Gene Id and Symbol Id, obtaining a differential mRNA expression matrix
(DE-mRNA matrix). Starting from the differentially expressed miRNAs (Supple-
mentary Data 1), we ﬁltered out the features with q> 0.01 and absolute log fold
change <1. For the remaining miRNAs (n= 40), we obtained the validated gene
targets from the mirTarBase database75. Since, even with these constraints, the gene
list was quite big (n= 9326), we decided to ﬁlter out genes that were not reported to
be downregulated by at least two miRNAs, obtaining the ﬁnal miRNA-targets gene
list (n = 5630). Finally, we extracted from the DE-mRNA matrix the log fold
change information corresponding to the obtained miRNA-targets gene list.
Then, we performed 1000 comparisons (using the Kolmogorov–Smirnov test
and Wilcoxon test) in which the control vector was composed by the log fold
change values randomly selected from the DE-mRNA matrix, while maintaining
the size of log fold change of the miRNA-targets gene list. The P-values were
adjusted using the Benjamini–Hochberg method. Notably, the statistical tests
were performed only on the one tail corresponding to the correct biological
direction (increase of the miRNA-targets gene expression with respect to the
control, P= 6 × 10−30 for KS test, and P= 0.0016 for Wilcoxon test). As a further
control, we also checked in the opposite direction (decrease of the miRNA-targets
gene expression with respect to the control), obtaining worst signiﬁcant results
(P= 10−15 for KS test and P= 1 for Wilcoxon test). Finally, we choose a
conservative approach to combine P-values averaging the log transformed P-values
instead of using Fisher’s method due to the dichotomous results (P= 0 for the
correct biological direction tests and P= 1 for opposite direction). Empirical
cumulative distribution function curves were calculated and plotted using the stats
package inside the R/Bioconductor environment76.
RNA immunoprecipitation. HeLa cell clones were seeded in 150-cm plates at a
density of 1 × 107 cells per plate. Two 150-cm plates for APE1WT-expressing cells
were grown. RIP2, 42 was carried out as detailed in the Supplementary Information.
Library preparation and sequencing. TruSeq Stranded Total RNA with
Ribo-Zero Human/Mouse/Rat (Illumina, San Diego, CA) was used for library
preparation following the manufacturer’s instructions. Both RNA samples and ﬁnal
libraries were quantiﬁed by using the Qubit 2.0 Fluorometer (Invitrogen) and
quality tested by Agilent 2100 Bioanalyzer RNA Nano assay (Agilent technologies,
Santa Clara, CA). Libraries were then processed with Illumina cBot for cluster
generation on the ﬂowcell, following the manufacturer’s instructions and
sequenced on 50 bp single-end mode with a HiSeq2500 apparatus (Illumina). The
CASAVA 1.8.2 version of the Illumina pipeline was used to process raw data for
both format conversion and de-multiplexing.
Transcriptomics analysis. Raw sequence ﬁles were subjected to quality control
analysis using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
The reads were quantiﬁed using Salmon77, 78 to the human reference transcriptome
GRCh38 obtained from the ENSEMBL web site. In particular, we utilized the
combined FASTA of cDNA and ncRNA. Salmon performs transcript-level
quantiﬁcation estimates from RNA-seq data; it achieves its accuracy and speed via a
number of different innovations, including the use of quasi-mapping (an accurate
but fast-to-compute proxy for traditional read alignments) and a two-phase
inference procedure that makes use of massively parallel stochastic collapsed
variation inference77, 78. The obtained results were gene quantiﬁcations at the
transcript level for each sample. Afterwards, we obtained differentially APE1-bound
transcript lists using edgeR and applying the recommend procedures for the
three comparisons (IP-APE1 vs. Input, IP-APE1 vs. IP-control, and, IP-control vs.
Input)79, 80. In order to minimize the false positive elements, we selected as
APE1-binding RNAs only the transcripts (n= 1015) that were detected as enriched
in both the IP-APE1 vs. Input comparison (fold change >2, FDR< 0.05) and
IP-APE1 vs. IP-control comparison (fold change FDR >2). Notably, none of these
transcripts was enriched in the IP-control vs. Input.
Functional analysis. Data were analyzed through the use of David/EASE46 and
QIAGEN Ingenuity Pathway Analysis (QIAGEN Redwood City, www.qiagen.com/
ingenuity). For IPA, transcripts were associated with biological functions/tran-
scriptional regulators in the Ingenuity Knowledge Base. miRNA targets prediction
was performed using the miRNA targets analysis included in IPA. A right-tailed
Fisher’s exact test was used to calculate a P-value to determine the probability that
each biological function/transcriptional regulator assigned to the data set was due
to chance alone.
Cancer specimens and immunohistochemistry. Ninety-four parafﬁn-embedded
cancerous tissue samples, including NSCLC, colorectal cancer, breast cancer,
cervical cancer, and glioblastoma, were collected from patients who underwent
surgical resection without prior chemotherapy or radiotherapy in Daping Hospital,
Third Military Medical University (Chongqing, China) from 2015 to 2016. This
study was approved by the Ethics and Research Committee of the Daping faculty of
Medicine, Third Military Medical University, Chongqing, China; written informed
consents were obtained from all patients. The Histopathological assessment was
carried out separately by two pathologists and then a consensus was made on
discordant assessments. Sections from formalin-ﬁxed and parafﬁn-embedded
(FFPE) tumors were incubated with APE1 antibody (clone 13B8E5C2; dilution
1:5000; Novus Biologicals) or PTEN antibody (clone A2B1; dilution 1:100; Santa
Cruz Biotechnology) overnight, at 4 °C. Sections were rinsed with phosphate-
buffered saline (PBS) and incubated with goat anti-mouse secondary antibody.
Sections were rinsed with PBS, developed with diaminobenzidine substrate, and
then counterstained with diluted Harris hematoxylin. APE1 and PTEN staining
were analyzed and scored for four categories: (i) score 0, no expression in tumor
cells; (ii) score 1+, faint/barely perceptible partial expression in <10% of tumor
cells; (iii) score 2+, weak to moderate expression in >10% of tumor cells; (iv) score
3+, strong expression in >10% of tumor cells. Image analysis was done by two
experienced pathologists independently. Statistical signiﬁcance was calculated
according to the Spearman’s rank correlation test.
Quantitative real-time reverse transcriptase-PCR. For the measurement of
mRNA-expression from cell lines, total RNA was extracted with the SV Total RNA
isolation System kit (Promega, Madison, WI). One microgram of total RNA was
reverse transcribed using the iScriptcDNA synthesis kit (Bio-Rad, Hercules, CA),
according to the manufacturer’s instructions. qRT-PCR was performed with a
CFX96 Real-Time System (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad).
Primers used were: FOSB For 5ʹ-AGCTAAATGCAGGAACCGG-3ʹ, FOSB Rev
5ʹ-ACCAGCACAAACTCCAGAC-3ʹ; NEIL For 5ʹ-GCCCTATGTTTCGTGGA-
CATC-3ʹ, NEIL Rev 5ʹ-CGCTAGGTTTCGTAGCACATTC-3; POLB For
5ʹ-AGTACACCATCCGTCCCTTG-3ʹ, POLB Rev 5ʹ-AAAGATGTCTTTTTCA
CTACTCACTG-3ʹ; PTEN For 5ʹ-AAGTCCAGAGCCATTTCC-3ʹ, PTEN Rev
5ʹ-AATATAGGTCAAGTCTAAGTCG-3ʹ; GAPDH For 5ʹ-CCTTCATTGACCT-
CAACTACATG-3ʹ, GAPDH Rev 5ʹ-TGGGATTTCCATTGATGACAAGC-3ʹ.
DNA was ampliﬁed in 96-well plates using the 2X iQ SYBR green supermix
(Bio-Rad) and 10 μM of the speciﬁc sense and antisense primers in a ﬁnal volume
of 15 μl for each well. Each sample analysis was performed in triplicate. As negative
control, a sample without template was used. The cycling parameters were
denaturation at 95 °C for 10 s and annealing/extension at 60 °C for 30 s (repeated
40 times). In order to verify the speciﬁcity of the ampliﬁcation, a melting-curve
analysis was performed, immediately after the ampliﬁcation protocol.
For pri-miRNA and mature miRNAs qRT-PCR analysis from in vitro cultured
cell lines, RNA was isolated using miRNeasy kit (Qiagen, USA), according to the
manufacturer’s instructions. For pri-miRNA and mature miRNAs assay from FFPE
samples, total RNA was extracted with the miRNeasy FFPE kit (Qiagen, USA). For
pri-miRNA analysis, 1 μg of total RNA was reverse transcribed using the
iScriptcDNA synthesis kit (Bio-Rad), according to the manufacturer’s instructions.
For mature miRNAs, TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems, Carlsbad, CA) was used. Brieﬂy, 10 ng of total RNA were coincubated
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with 1 µl of miRNA-speciﬁc primers (Assay-ID miR-221: 000524; miR-222:
002276; RNU44: 001094) and cDNA generated in the presence of RNase-
inhibitors. Detection of successfully transcribed products was carried out using
TaqMan2x Universal PCR Mix (no AmpErase UNG; Applied Biosystems) in
combination with miRNA-speciﬁc primers and TaqMan-probes, and quantiﬁed on
a Lightcycler 480 (Roche Applied Sciences). RT-qPCR results were calculated using
the ΔΔct method, utilizing the expression of RNU44 and GAPDH as the
housekeeping gene for mature miRNA and pri-miRNA, respectively.
Isolation and quantiﬁcation of abasic RNA. Oxidatively depurinated/depyr-
imidinated RNA species were speciﬁcally labeled with an ARP, and isolated with
streptavidin magnetic-beads based on the previous report43. In vitro synthesized
RNA encoding Xenopus elongation factor 1α gene was added to the total RNA
isolated from HeLa cells to 30 µg in total amount. The RNA was derivatized with
2 mM ARP in 50 mM Na acetate buffer pH 5.2 for 40 min, at 37 °C, and
precipitated by ethanol. After resuspending with deionized water, an aliquot was
put aside for quantifying total transcripts, and the rest of RNA was incubated with
streptavidin magnetic-beads for 20 min, at 60 °C. After washing with wash buffers
including urea, oxidized RNA was dissociated from beads by incubating with
2.5 mM biotin solution at 90 °C, for 5 min, and precipitated by ethanol. The
precipitated oxidized RNA and total RNA were used for cDNA synthesis (Single
strand cDNA synthesis kit with DNase, Thermo Fisher Scientiﬁc). Complementary
DNA was employed for qRT-PCR with GTXpress Master mix and TaqMan probe
for miR-221 or miR-222 (Hs03303007_pri or Hs03303011_pri, Thermo Fisher
Scientiﬁc) using LightCycler 480, according to the manufacturer’s protocol. The
oxidation levels of miRNAs were determined based on ΔCq values between Cq of
total RNA and oxidized RNA. Speciﬁcity of the qRT-PCR was conﬁrmed by Tm
temperature and by testing without reverse transcription. PCR ampliﬁcation was
assessed by calibration curve using serial dilution method.
Preparation of cell extracts and protein quantiﬁcation. For preparation of total
cell lysates, cells were collected by trypsinization and centrifuged at 250 × g for
5 min, at 4 °C. Supernatant was removed, and the pellet was washed once with
ice-cold PBS and then centrifuged again as described before. Cell pellet was
resuspended in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, and 1% w/v Triton X-100 supplemented with 1× protease inhibitor
cocktail (Sigma), 0.5 mM phenylmethylsulfonyl ﬂuoride (PMSF), 1 mM NaF and
1mM Na3VO4 for 30 min, at 4 °C. After centrifugation at 12,000 × g for 30 min, at
4 °C, the supernatant was collected as total cell lysate. The protein concentration
was determined using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA).
Blots were developed by using the NIR Fluorescence technology (LI-COR GmbH,
Germany) or the ECL enhanced chemiluminescence procedure (GE Healthcare,
Piscataway, NJ), the latter case indicated in each ﬁgure capture. Images were
acquired and quantiﬁed by using an Odyssey CLx Infrared Imaging system
(LI-COR GmbH, Germany) or by using a Chemidoc XRS video densitometer (Bio-
Rad, Hercules, CA), respectively. Original uncropped images of western blots used
in this study can be found in Supplementary Figs. 10 and 11.
Antibodies and western blotting analysis. For western blotting analyses, whole-
cell lysates were prepared and 20 µg of proteins were resolved on 12% SDS–PAGE,
transferred onto nitrocellulose membranes (Schleicher & Schuell Bioscience,
Dassel, Germany) and probed with antibodies for PTEN (sc-7974; Santa Cruz
Biotechnology, Santa Cruz, CA) (1:1000), APE114 (1:1000), FLAG (F1804, SIGMA)
(1:5000), Akt1 (sc-1618, Santa Cruz Biotechnology) (1:1000) and p-Akt1/2/3
(Ser473)(sc-7985-R; Santa Cruz Biotechnology) (1:1000). Data normalization
was performed by using monoclonal anti-actin and anti-tubulin (Sigma-Aldrich)
as indicated. The corresponding secondary antibodies labeled with IR-Dye
(anti-rabbit IgG IRDye 680 and anti-mouse IgG IRDye 800) were used. Detection
and quantiﬁcation was performed with the Odyssey CLx Infrared imaging system
(LI-COR GmbH, Germany). The membranes were scanned in two different
channels using an Odyssey IR imager; protein bands were quantiﬁed using Odyssey
software (Image Studio 5.0) and the relative signal, expressed as ratio of the treated
group over the control group, was calculated.
Immunoﬂuorescence confocal and proximity ligation analyses. Immuno-
ﬂuorescence procedures and PLA were carried out as described earlier41, 42. To
study the interaction between APE1 and DROSHA in vivo, we used the in situ
Proximity Ligation Assay technology (Duolink, Sigma-Aldrich). After incubation
with monoclonal anti-APE1 (1:22)14 for 3 h, at 37 °C, cells were incubated with
polyclonal anti-DROSHA (ab85027, Abcam, Cambridge, MA)(1:200) overnight, at
4 °C. PLA was performed following the manufacturer’s instructions. Technical
controls, represented by the omission of anti-DROSHA primary antibody, resulted
in the complete loss of PLA signal. Cells were visualized through a Leica TCS SP
laser-scanning confocal microscope (Leica Microsystems). Determination of PLA
signal was performed using the Blob Finder software (Center for Image Analysis,
Uppsala University).
AP-site incision assays. APE1 endonuclease activity was monitored using HeLa
cell extracts as follows:13, 34. Brieﬂy, enzymatic reactions were carried out in a
ﬁnal volume of 10 µl using 12.5 ng of cell extracts in a buffer containing 50 mM
Tris-HCl pH 7.5, 50 mM KCl, 10 mM MgCl2, BSA (1 μg ml−1), and 1 mM DTT.
Extracts were incubated for 15 min, at 37 °C, with 100 nM of double-stranded
26-mer abasic DNA substrate containing a single tetrahydrofuranyl artiﬁcial AP
site at position 14, which is cleaved to a 14-mer in the presence of AP endonuclease
activity34. The double-strand DNA was obtained by annealing a 5ʹ-DY-782-labeled
oligonucleotide 5ʹ-AATTCACCGGTACCFTCTAGAATTCG-3ʹ (where F
indicates the tetrahydrofuran residue), with an unlabeled complementary sequence
5ʹ-CGAATTCTAGAGGGTACCGGTGAATT-3ʹ.
Reactions were halted by addition of formamide buffer (96% formamide,
10 mM EDTA and gel Loading Buffer 6× (Fermentas)), separated onto a 20% (w/v)
denaturing polyacrylamide gel and analyzed on an Odyssey CLx scanner (Li-Cor
Biosciences). The percentage of substrate converted to product was determined
using the ImageStudio software (Li-Cor Biosciences).
APE1-interactome analysis. Immunopuriﬁed protein material from endogenous
APE1-silenced HeLa cells expressing APE1WT or APE1NΔ33 and grown under
different experimental conditions, or from endogenous APE1-silenced HeLa cells
stably transfected with the empty vector and expressing a scrambled siRNA
sequence (APE1SCR) were analyzed in parallel by SDS–PAGE. After colloidal
Coomassie staining, whole-gel lanes were cut into six slices, minced, and washed
with water. Corresponding proteins were separately in-gel reduced, S-alkylated
with iodoacetamide, and digested with trypsin, as detailed in Supplementary
Information.
Statistical analyses. All reported values are represented as the mean± SD of three
biological replicates. Statistical analyses were performed by using the Student’s
t-test. P< 0.05 was considered as statistically signiﬁcant. The use of other statistical
tests has been indicated where required.
Data availability. Illumina reads are deposited into NCBI Sequence Read Archive
under accession number SRP078114. The data that support the ﬁndings of this
study are available from the corresponding author on request.
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